See the people that are working to make bio-engineered livers possible.
Dr. Basak Uygun
Harvard Medical School
Dr. Uygun is an Instructor in Surgery at Harvard Medical School and Massachusetts General Hospital. Previously she spent five years as a Postdoctoral Research Fellow at Mass General and Shriners Hospital for Children in Boston. In 2011, Dr. Uygun was honored by the National Institutes of Health's Pathway to Independence Award for her work using discarded livers as natural scaffolds to create liver grafts. These transplantable grafts showed normal liver function for up to 10 days and were introduced into rats. The findings of this proof of concept study were published in a 2010 article authored by Dr. Uygun and a team of researchers at Mass General. She is the author/co-author of 22 published articles.
Dr. Stephen Badylak
University of Pittsburgh
Dr. Badylak is Deputy Director of the McGowan Institute for Regenerative Medicine, Director of the Center for Preclinical Testing, and directs a laboratory focused on the use of biological scaffolds composed of extracellular matrix (ECM) to facilitate functional tissue regeneration. Dr. Badylak is the immediate-past President of the Tissue Engineering and Regenerative Medicine International Society, author of more than 275 peer reviewed publications, and holds more than 50 issued U.S. patents and 300 patents worldwide.
The focus of his work has been the mechanisms by which ECM signals host tissues to promote and support functional tissue reconstruction. Dr. Badylak places emphasis on clinical translation of all activities in the laboratory and work conducted within the laboratory spans the full spectrum from basic science at the subcellular level to patient care at the bedside.
Dr. Takanori Takebe
Yokohama City University
Dr. Takebe was recently named an Associate Professor at the Yokohama City University Graduate School of Medicine. At 26, he is one of the youngest faculty members in Japan. Dr. Takebe is also a Visiting Associate Professor at Stanford University’s Institute for Stem Cell Biology and Regenerative Medicine; a Visiting Scientist at RIKEN Center for Developmental Biology; a Project Leader at the Yokohama City University Advanced Medical Research Center; a Researcher at PRESTO, a Japan Science and Technology Agency; and a Researcher with Mirai Design Lab. He was co-leader on a study that coaxed induced pluripotent stem cells (IPSCs) to grow into small human liver buds in mice.
Dr. Hiro Nakauchi
Dr. Nakauchi obtained a M.D. from Yokohama City University School of Medicine and a Ph.D. in immunology from University of Tokyo Graduate School of Medicine. He isolated CD8 genes during his post-doc period at the Laboratory of Prof. Leonard Herzenberg at Stanford University. After returning to Japan, he started working on hematopoietic stem cells in his laboratory at RIKEN. In 1994, he became Professor of Immunology at the University of Tsukuba where he demonstrated that a single hematopoietic stem cell could reconstitute the entire hematopoietic system, a definitive experimental proof for the “stemness”. Since April 2002, he has been a Professor of Stem Cell Therapy in the Institute of Medical Science at The University of Tokyo (IMSUT). In 2008, he was appointed Director of newly established Center for Stem Cell Biology and Regenerative Medicine at IMSUT. Recently, he returned to Stanford University as a faculty to continue his stem cell research at the Institute of Stem Cell Biology and Regenerative Medicine. Goals of his work are to translate discoveries in basic research into practical medical applications.
Dr. Eric Lagasse
University of Pittsburgh
Dr. Lagasse is an Associate Professor in the Department of Pathology at the University of Pittsburgh, with a secondary appointment in Pitt’s Clinical and Translational Institute. He is also the Director of the Cancer Stem Cell Center at the McGowan Institute. His laboratory research is focused primarily on stem cell biology and cell-based therapy for a variety of diseases including cancer.
Dr. Lagasse’s specific research interests include: cell-based therapy for liver disease, ectopic organogenesis, bioartificial tumors development, and identification of normal and cancer stem cells. He is the author of over 40 publications including four book chapters. In 2010, his work on organogenesis was featured on the Discovery Channel, ”Dean of Invention: Growing New Organs Inside the Body.“ In 2012, Discover Magazine featured his work in ”Big Idea: Turning Lymph Nodes Into Liver-Growing Factories.“
Dr. Tahera Ansari
Dr. Ansari is a Senior Post-Doctoral Scientist at Northwick Park Institute for Medical Research (NPIMR), a medical charity in the UK. She is a basic scientist focused on regenerative medicine, specifically tissue engineering of functional tissue using biological scaffolds and autologous cells of different lineages. Her team has an interest in respiratory and gastroenterology and has developed two scaffolds being assessed in human phase I clinical trials.
Dr. Bryon Peterson
University of Florida
Dr. Petersen is a Professor in the Department of Pediatrics at the University of Florida’s College of Medicine. He has been recognized worldwide as a foremost authority in hepatic stem cells and their role in liver pathology. Dr. Petersen’s seminal paper in Science (Science 284: 1168-1170) showed that bone-marrow-derived cells could become functioning hepatocytes. He is currently conducting research in stem cell biology and how it relates to the patho-physiology of the liver. His current research also includes the development of a bioartificial liver device. Using decellularized liver as a building block, his research team is investigating how mature cells and stem cells can be utilized in regenerating functional hepatic tissue. Dr. Petersen has authored or co-authored over 80 peer-reviewed papers and nine book chapters, and has been honored with several national and international awards.
Dr. John Geibel
Dr. Geibel is Vice Chairman of the Department of Surgery at Yale University School of Medicine and Director of Surgical Research and Professor of Cellular and Molecular Physiology. He holds a Bachelors of Science Degree in Physiology, an MD and DSc degree as well as a Master’s of Science, and a Master’s of Arts Degree. Professor Geibel’s active research interests are on the role of the Calcium Sensing Receptor (CaSR) in gastrointestinal physiology and pathophysiology. In addition, Dr. Geibel has conducted research in fluid and electrolyte transport in the intestine. Professor Geibel is the author of over 150 publications and presents his findings both nationally and internationally. He is the holder of seven patents on the role of the calcium sensing receptor on gastrointestinal models and is currently actively working to begin clinical trials on a method to stop secretory diarrhea in the developing world based on targeting the calcium sensing receptor.
Dr. Clifford Steer
Clifford Steer, MD, Professor of Medicine and Genetics, Cell Biology and Development, University of Minnesota
Dr. Clifford J. Steer received his M.D. and internal medicine training from the University of Minnesota. He spent 14 years at the NIH as a clinical hepatologist and basic researcher. He is presently a Professor of Medicine and Genetics, Cell Biology and Development; and is also a member of several graduate school programs and the College of Vet Medicine. He is a long-standing member of NIH study sections, and has co-authored 245 articles. His research career in liver diseases has spanned more than 35 years and he continues to do work in liver regeneration. His research has been written up in newspapers around the world, including Time magazine. He is the past recipient of the Department of Medicine Faculty Award for Outstanding Research, and the Senior Investigator Award from the University of Minnesota Medical School. In 2014 he was made an inaugural Fellow of the American Association for the Study of Liver Diseases.
Dr. Rajagopal N. Aravalli
Raj Aravalli, PhD, Assistant Professor, University of Minnesota
Dr. Rajagopal N. Aravalli received his Ph.D. in molecular biology from the University of Copenhagen, Denmark. He is presently an Assistant Professor of Radiology at the University of Minnesota Medical School. His research interests are focused on the role of stem cells in liver diseases and in liver regeneration. In addition to iPS cells, his projects involve primary liver stem cells and cell lines of rodent, porcine, and human origins.
Dr. Geoffrey Gurtner
MD, Johnson & Johnson Distinguished Professor of Surgery, Stanford University
Dr. Geoffrey C. Gurtner is the Johnson and Johnson Distinguished Professor of Surgery and Professor of Materials Science and Engineering (by courtesy) at Stanford University. He serves as the Associate Chairman for Research in the Department of Surgery and is the Executive Director of the Stanford Wound Care Center. Dr. Gurtner is a magna cum laude graduate of Dartmouth College and an AOA graduate of the University of California San Francisco School of Medicine. He completed a general surgery residency at Massachusetts General Hospital, a plastic surgery residency at NYU School of Medicine, and received advanced training in microsurgery at the University of Texas-MD Anderson Cancer Center. He is board certified in both general surgery and plastic surgery. Dr. Gurtner is the author of over 180 peer-reviewed publications, editor of two major surgical textbooks, founder of several venture backed start-up companies, and holds numerous U.S. patents. The Gurtner Laboratory focuses on a diverse range of translational research areas including stem cell biology, cell-based therapy, advanced biomaterials, and tissue engineering. Dr. Gurtner’s work is deeply driven by clinical need and a fundamental goal of all laboratory activity is clinical translation.
Dr. Michael Findlay
MBBS PhD FRACS FACS, Visiting Assistant Professor, Department of Surgery, Stanford University
Dr. Peter A. Than
MD, Postdoctoral Fellow, Resident Physician, Department of Surgery, Stanford University
Dr. Peter A. Than is a resident physician in the general surgery training program and post-doctoral research fellow at Stanford University Medical Center. He is a summa cum laude graduate of the University of Florida and received his M.D. from Brown University. Dr. Than has a clinical interest in organ transplantation and hepatobiliary surgery. His research focuses on strategies to produce vascularized tissue- engineered replacement organs. He is currently investigating techniques to develop functional autologous hepatic replacement tissue. Dr. Than’s work in tissue engineering has been recognized with a Resident Research Award from the American College of Surgeons.
Dr. Christopher R. Davis
MB ChB MRCS, Postdoctoral Fellow, Department of Surgery, Stanford University
Dr. Christopher R. Davis is a specialist registrar in plastic and reconstructive surgery in the United Kingdom. He came to Stanford University as a Fulbright Scholar to pursue translational research on therapeutic microsurgical reconstruction following ablative surgery for cancer. His expertise in free tissue transfer led him to work on regenerative and therapeutic applications of free flaps. Dr. Davis is the recipient of numerous awards from the Royal College of Surgeons of England, British Association of Plastic, Reconstructive & Aesthetic Surgeons, and Royal Society of Medicine, in addition to an International Young Investigator Award.
Dr. Mordechai Saeid Nosrati
MD, Associate Professor of Medicine, Department of Medicine, Division of Nephrology, Keck-USC School of Medicine
Dr. Nosrati earned his MD degree from State University of New York in Brooklyn in 1987. He then continued to complete his postdoctoral clinical training in Internal Medicine (internship and residency program) in at Montefiore Medical Center, Albert Einstein School of Medicine, in Bronx, NY. Dr. Nosrati was then awarded a nephrology fellowship at Beth Israel Hospital/ Harvard Medical School in Boston, MA. After completing his fellowship in Nephrology, Hypertension and Transplantation in 1992, Dr. Nosrati joined the Keck-USC School of Medicine in Los Angeles, CA in as an Assistant Professor of Medicine. He is currently an Associate Professor of Medicine at Keck-USC School of Medicine in Los Angeles, CA. He has been Medical Director of the CKD program and the Renal, Hypertension and Transplant Clinic at the LAC+USC for more than twenty two years. Dr. Nosrati has also served as Medical Director of the Peritoneal Dialysis Program and Home Hemodialysis Program at the USC Dialysis Center and has been an attending physician at the CAPD Clinic, USC Outpatient Dialysis, and LAC+USC Medical Center in Los Angeles CA. He has been actively involved in a number of bench research as well as clinical research activities spanning different fields of medicine for more than twenty two years. He has been conducting extensive clinical research mostly phase III and Phase IV industry sponsored clinical trials in Medicine and Nephrology. Moreover, he has been actively conducting major pharmaceutical sponsored phase II-IV clinical trials in hypertension, anemia, iron, secondary hyperparathyroidism etc. Dr. Nosrati also has broad and wide-ranging clinical experience in treating many patients in an extremely busy Level 1 trauma center as well as a primary and tertiary referral medical center covering more than 120 critical care beds. He has been treating many patients on daily basis who suffer from CKD and ESRD as well as many patients suffering from multiorgan failure conditions. Moreover, he has extensive experience in treating patients with acute kidney injury (AKI), chronic kidney disease (CKD), end stage renal disease (ESRD) and end stage liver disease (ESLD), and multi-organ failure (MOF)/multi-organ dysfunction syndrome (MODS). He also has wide-ranging experience , using advanced modalities of dialysis and most specifically renal replacement therapies (RRT) including Intermittent hemodialysis (IHD), isolated ultrafiltration (IUF), sustained/slow low efficiency daily dialysis (SLEDD), sustained/slow low efficiency daily dialysis with ultrafiltration (SLEDDF), continuous veno-venous hemofiltration(CVVH), continuous veno-venous hemodialysis (CVVHD),etc. Furthermore, Dr. Nosrati is actively conducting research in advancing kidney dialysis, liver dialysis and providing a support system for the MOF/MODS multisystem failures using advanced technologies.
Dr. Toshio Miki
MD, PhD, Assistant Professor of Research, Department of Biochemistry and Molecular Biology, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck-USC School of Medicine
Dr. Miki earned his PhD in Biochemistry from Nihon University School of Medicine, Tokyo, Japan, in 1998. He then completed his medical education and earned an MD degree from Nihon University, School of Medicine, Tokyo, Japan, in 1992. He then continued as clinical faculty at Nihon University till 2002 when he joined the faculty of the University Of Pittsburgh School of Medicine from 2002-2008. Dr. Miki then joined the USC School of Medicine as an assistant professor of research in the Department of Biochemistry and Molecular Biology. He is a trained liver surgeon and has been conducting basic research in human pluripotent stem cells (hPSCs) for more than 6 years. He has also studied 3D liver bioreactors at the University of Pittsburgh for 3 years. He has published more than 30 peer reviewed research papers, including “Hepatic differentiation of human embryonic stem cells in promoted by 3D dynamic perfusion culture conditions.” His laboratory at the USC Broad CIRM Center is capable of conducting induction and validation assays for hPSC-derived hepatocytes. In addition, as a member of the NIH Research Center for Liver Diseases at USC, he has access to all center equipment in order to evaluate hPSC-derived hepatocytes. The infrequent and unpredictable supply of human primary hepatocytes will be one of the obstacles to achieve the goal of this project. Dr. Miki will be able to supply hPSC-derived hepatocyte and non-parenchymal cells to generate implantable artificial liver organs.
Dr. Emil Kartalov
MS, PhD, Assistant Professor of Pathology, Department of Pathology, Keck-USC School of Medicine
Dr. Kartalov earned his B.S. in Physics (1998), M.S. in Applied Physics (2004), and later on he completed his Ph.D. studies in Applied Physics (2004), all from California Institute of Technology. His doctoral thesis focuses on single-molecule fluorescence microscopy, single-molecule DNA sequencing, and microfluidic DNA sequencing by synthesis. The first two developed techniques resulted in the founding of Helicos Biosciences in Boston, MA. For his postdoctoral work, Dr. Kartalov moved to the Biochemistry Dept. Dr. Kartalov invented microfluidic vias and resultant auto-regulatory devices, and built multi-analyte microfluidic immunoassay chip for protein diagnostics in finger-prick amounts of human serum and plasma. In 2006, Dr. Kartalov won the NIH K99/R00 Career Award and became tenure-track faculty in Pathology at USC in 2008. Dr. Kartalov is currently an Assistant Professor of Pathology at Keck-USC School of Medicine where he has focused on fundamental microfluidics and biomedical applications of microfluidic devices. He has over 15 years of experience in microfluidics, nanotechnology, biotechnology, and molecular diagnostics. He has a well-established and productive state-of-the-art research laboratory of at USC, as well as full unrestricted access to state-of-the-art nanotechnology fabrication facilities at California Institute of Technology, where Dr. Kartalov is a visiting faculty. His group focuses on microfluidic point-of-care diagnostics and techniques for high-throughput analysis of pathology tissue slices. Dr. Kartalov has 19 peer-reviewed publications and 11 issued patents.
Dr. Noah Malmstadt
BS, PhD, Associate Professor of Chemical Engineering and Material Sciences, Mork Family Department of Chemical Engineering and Materials Science, University of Southern California
Dr. Malmstadt is an Associate Professor of Chemical Engineering and Materials Science with joint appointments in Chemistry and Biomedical Engineering at USC. He received his BS in Chemical Engineering from Caltech and his PhD in Bioengineering from the University of Washington. He has been the PI on over 3.5M in federal grants (NSF, NIH, DoD) since 2007. He has deep fluency is the development of microfluidic systems for performing biophysical analysis and microreactor design. He is a leader in the application of 3D printing technology for microfluidics fabrication and led the development of the modular platform that we are proposing to apply here. Additionally, he has expertise in using microfluidics for automated synthesis systems. His 33 papers have been cited a total of over 1000 times.
Dr. Tae-Joon Jeon
BS, PhD, Associate Professor of Biological Engineering, Department of Biological Engineering, Inha University, Korea
Dr. Jeon received his B.S. degree with honors (Manga Cum Laude) in the Department of Chemical Engineering from Seoul National University, Korea, in 2001 and then he completed his Ph.D. in the Department of Chemical and Biomolecular Engineering from University of California, Los Angeles in 2008, followed by his postdoctoral work in the Department of Bioengineering at UCLA. Prior to his graduate studies at UCLA, he worked for IBM as a business analyst. His doctoral thesis focuses on building robust biomimetic membrane structure for ion channel studies and single molecule sensing applications. During his graduate studies, he developed several membrane platforms, which resulted in the founding of Librede, Inc. in San Diego, CA. Additionally, he had served as a Consultant and Science Advisory Board Member for AquaZ A/S, previously Danfoss AquaZ A/S, in Denmark from 2009 to 2012, where he suggested several techniques of interfacing abiotic and biotic components to construct an aquaporin embeded water purificaiton system by mimicking biological cells. In 2008, he joined as faculty member in the Department of Biological Engineering at Inha University, Korea. He is currently an Associate Professor and Vice Director of Biohybrid Systems Center at Inha University. He has been a PI / co-PI for research grants mostly funded by Korean government over 3.8M since 2009. His ongoing research focuses on biochips / biosensors, membrane biophysics, artificial cells, ion channels, and liposomes/vesosomes. Additionally with comprehensive skills and knowledge on fabrication of microsystems, he has built numerous 3-D model systems of organs on a chip including heart muscles, skins, and liver, which will lead to substantial contributions and fruitful outcomes to the project that we are proposing. He will also be able to fabricate and interface multi-layered platforms composed of a number of microfluidic platforms and membranes. He has 36 peer-reviewed research articles including 2 papers in press and 23 patent applications with 9 issued patents, most of which are closely relevant to the project we are proposing here. His papers have been cited a total of over 700 times.
Dr. Jeff Ross
Miromatrix Medical Inc., VP of Product Development
Dr. Ross has more than a decade of research and product development experience in regenerative medicine and medical devices. He holds a Master’s degree in Biomedical Engineering with a focus on tissue engineering and a Ph.D. in Molecular, Cellular and Developmental Biology where he studied stem cell differentiation. Dr. Ross started his industry career at Guidant leading a biologics group for new cardiovascular therapies. Following Guidant, he worked at Athersys assisting with the commercialization and scale up of stem cell technologies. Recently he was Director of Research and Commercial Development of Biologics at SurModics. He has extensive experience in early development, preclinical, commercialization and clinical practices. Dr. Ross has over 30 published and issued patents along with leading publications in Nature and the Journal of Clinical Investigation.
Scott L. Nyberg
The research of Scott L. Nyberg, M.D., Ph.D., is focused on the development of a multidisciplinary bioartificial liver program to improve the treatment of patients with liver failure and support the Mayo Clinic clinical liver transplant program.
His lab is also involved with regenerative medicine of liver disease as it pertains to treating patients in liver failure with extracorporeal bioartificial livers or implantable tissue-engineered livers, or treating patients with metabolic liver disease with hepatocyte transplantation.
Allan B. Dietz
Allan B. Dietz and his lab are focused on getting novel therapies to patients. As a Co-Director of the Human Cell Therapy Lab within Mayo's Center for Regenerative Medicine, Dr. Dietz focuses on the use of cells as drugs. To that end, the lab is involved in clinical trials using dendritic cell vaccines to promote immunity and mesenchymal stromal cells (adult stem cells) to suppress immunity and enhance tissue repair.
Dr. Dietz's lab supports these trials by developing methods to grow and characterize these cells; characterizing patients' immune status; and monitoring therapy-induced changes in that status. During the course of these studies Dr. Dietz and his colleagues have described the immunosuppressive effects of monocytes and seek to understand their generation and consequence.
Dr. Rajmohan Gopimohan
Polyskin Lifesciences India Pvt Ltd.
Dr. Rajmohan is a doctor with PhD in tissue engineering from National Institute of Immunology, India. He founded the company, Polyskin Lifesciences that focus on innovative solutions in health care using principles of tissue engineering and regenerative medicine.